News
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response
- Details

UroMems Completes €23 Million Series B Financing
- Details

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs
- Details
